<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[schering Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/schering.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to schering]]></description>
	<s:counts start="0" returned="20" found="51" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Schering's Say-on-Pay Survey Goes M.I.A.]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004629/scherings-say-on-pay-survey-goes-mia/]]></link>
		<description><![CDATA[Did Schering-Plough plan -- and then kill or delay -- a "say on pay" survey of its investors? That's one possibility raised by "Condor" at Shearlings Got Plowed, the blog that obsessively examines goings-on at the company that's soon to be merged into Merck. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 05 Oct 2009 18:29:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Schering's Weird New Nuvaring Ad: "Don't You Have to ... Put It In ...?"]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003879/scherings-new-nuvaring-commercial-dont-you-have-to-put-it-in/]]></link>
		<description><![CDATA[Schering-Plough's new TV commercial for Nuvaring employs a weird strategy -- it features a group of women explaining the old Nuvaring commercial as it plays in the background video below. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 25 Aug 2009 18:48:27 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/gender+and+diversity.html"><![CDATA[Gender And Diversity]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/tvs.html"><![CDATA[TVs]]></category>
		<category domain="http://resources.bnet.com/topic/tv+%2526+home+theater.html"><![CDATA[Tv & Home Theater]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/home+entertainment.html"><![CDATA[Home Entertainment]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Does J&J's Move on Remicade Pact Threaten Schering CEO Hassan's $51 Mil. Merger Payout?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002268/does-jjs-move-on-remicade-pact-threaten-schering-ceo-hassans-51-mil-merger-payout/]]></link>
		<description><![CDATA[Johnson & Johnson filed with an arbitrator to unravel its Remicade distribution agreement with Schering-Plough, in light of the latter's merger with Merck. Schering argues there is no change of control in the agreement, a move which may threaten Schering CEO Fred Hassan's $51 million merger payout. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 21 May 2009 08:09:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[Merger]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/payout.html"><![CDATA[Payout]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Schering's Nuvaring Accused in Death; J&J's Ortho Evra Reveals a Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001917/scherings-nuvaring-accused-in-death-jjs-ortho-evra-reveals-a-worst-case-scenario/]]></link>
		<description><![CDATA[If Schering-Plough wants to know what the future possibly holds for its Nuvaring contraceptive -- accused in lawsuits of killing a woman via a thromboembolism -- it might want to look at what happened with Johnson & Johnson's Ortho Evra birth control patch. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 04 May 2009 09:30:05 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Merck-Schering: SEC Launches Insider Trading Probe]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001893/merck-schering-sec-launches-insider-trading-probe/]]></link>
		<description><![CDATA[The SEC has launched an insider trading probe around Schering-Plough and its March merger agreement with Merck, according to the WSJ. Stock in SGP jumped 8 percent on Friday March 6; the merger was announced on Monday March 9.    This graphic shows that on Thursday, SGP stock...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 30 Apr 2009 11:13:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/insider.html"><![CDATA[Insider]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[J&J vs. Merck and Schering: Who Is Most Desperate in This Bizarre Love Triangle?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001821/jj-vs-merck-and-schering-who-is-most-desperate-in-this-bizarre-love-triangle/]]></link>
		<description><![CDATA[Nobody wants to say anything about the great Remicade tug of war that has broken out between Johnson & Johnson and the soon-to-be-merged Merck and Schering-Plough.    A look at the Q1 2009 numbers suggest that each member of this trio has their own reasons to be quietly...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 24 Apr 2009 12:56:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/remicade.html"><![CDATA[Remicade]]></category>
		<category domain="http://resources.bnet.com/topic/merger+partner.html"><![CDATA[Merger Partner]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">JNJ,MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck-Schering Roundup: Layoffs More Likely at Schering; Insiders Traded Fortuitously; How Merck Timed the Deal]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001318/merck-schering-roundup-layoffs-more-likely-at-schering-insiders-traded-fortuitously-how-merck-timed-the-deal/]]></link>
		<description><![CDATA[LAYOFFS? In the Merck/Schering-Plough merger, layoffs will likely fall most heavily on the Schering employees. This is not just because Merck is the acquiring company and will place its people in the driving seats. (That, of course, will be part of it.)    Rather, it's because Schering has...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 10 Mar 2009 07:34:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001309/schering-ceo-hassan-has-59-million-buyout-agreement-in-merck-merger/]]></link>
		<description><![CDATA[Schering-Plough CEO Fred Hassan stands to receive a potential $59 million payout in his company's merger with Merck, according to a filing with the SEC. The golden parachute comes as the new Merck-Schering entity prepares for $3.5 billion in job cuts and other efficiencies.    In Schering's 2008...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 09 Mar 2009 08:21:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/payment.html"><![CDATA[Payment]]></category>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[Merger]]></category>
		<category domain="http://resources.bnet.com/topic/proxy+statement.html"><![CDATA[Proxy Statement]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/cost+savings.html"><![CDATA[Cost Savings]]></category>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[Agreement]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/sgp.html"><![CDATA[SGP]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough's Productivity (Layoffs) Program Has Murky Results]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000976/schering-ploughs-productivity-layoffs-program-has-murky-results/]]></link>
		<description><![CDATA[When Schering-Plough declared its Q4 2008 earnings a few days ago, the management team there got about half-a-dozen questions about the company's sales and marketing expenses -- more than the usual number.    Schering has played up its Productivity Transformation Program to Wall Street, which is essentially a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 12 Feb 2009 12:18:54 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/supply+chain.html"><![CDATA[Supply Chain]]></category>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/sg%2526a.html"><![CDATA[SG&A]]></category>
		<category domain="http://resources.bnet.com/topic/ptp.html"><![CDATA[PTP]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/supply+chain+management+%2528scm%2529.html"><![CDATA[Supply Chain Management (SCM)]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough, Sepracor Sign Deal to End Clarinex Exclusivity in 2012]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000542/schering-plough-sepracor-sign-deal-to-end-clarinex-exclusivity-in-2012/]]></link>
		<description><![CDATA[Schering Plough and Sepracor have settled a patent dispute with Indian generics maker Dr. Reddy's over Clarinex. The settlement brings forward the end of patent exclusivity on Clarinex to 2012. Previously, the assumption had been that Schering's exclusivity with Clarinex would last until 2020.    The terms of...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 29 Dec 2008 16:35:55 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/exclusivity.html"><![CDATA[Exclusivity]]></category>
		<category domain="http://resources.bnet.com/topic/clarinex.html"><![CDATA[Clarinex]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/clarinex+patent.html"><![CDATA[Clarinex Patent]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">SGP,SEPR</category>
	</item>
	<item>
		<title><![CDATA[Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000153/should-we-be-surprised-that-schering-plough-execs-are-surprised-by-sugameddex-rejection/]]></link>
		<description><![CDATA[Yet another setback for Schering-Plough seems to have taken top management by surprise. Scheringâ€™s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA.    In a statement, Schering VP Thomas Koestler said he was â€œsurprised...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 01 Aug 2008 13:13:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/diversity.html"><![CDATA[Diversity]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/nuvaring.html"><![CDATA[NuvaRing]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough Now in the Feds' Crosshairs]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2699&messageID=13002&start=0]]></link>
		<description><![CDATA[Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Thu, 10 Jul 2008 17:19:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/trial+result.html"><![CDATA[trial result]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2684&messageID=12779&start=0]]></link>
		<description><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Mon, 07 Jul 2008 14:41:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[How Pharma Stacks the Deck with Medical Journals]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2548&messageID=12068&start=0]]></link>
		<description><![CDATA[How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Wed, 18 Jun 2008 21:31:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/trial+result.html"><![CDATA[trial result]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
	</item>
	<item>
		<title><![CDATA[Schering's CEO, a Failed Trial and $16 Million]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100078/scherings-ceo-a-failed-trial-and-16-million/]]></link>
		<description><![CDATA[Forbes' Matthew Herper and Michael Maiello have just jumped on a subject we alluded to -- perhaps too obliquely -- a few weeks back in discussing the eye-popping $30 million Schering-Plough CEO Fred Hassan pulled down in 2007. Not only did Schering post a $1.5 billion loss that year, it...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 20 May 2008 04:19:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Fred Hassan, Schering's $30 Million Man]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100045/fred-hassan-scherings-30-million-man/]]></link>
		<description><![CDATA[Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 24 Apr 2008 15:39:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/shareholder.html"><![CDATA[Shareholder]]></category>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/performance.html"><![CDATA[Performance]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/performance+management.html"><![CDATA[Performance Management]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100043/is-merck-hanging-schering-out-to-dry-on-vytorin/]]></link>
		<description><![CDATA[A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin.    Vytorin, of course, is a combination...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 23 Apr 2008 14:25:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cholesterol.html"><![CDATA[Cholesterol]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Marketing Trumps Science in Vytorin Scandal]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100018/marketing-trumps-science-in-vytorin-scandal/]]></link>
		<description><![CDATA[In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 09:37:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zetia.html"><![CDATA[Zetia]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Marketing Trumps Science in Vytorin Scandal]]></title>
		<link><![CDATA[http://blogs.bnet.com/intercom/?p=1721]]></link>
		<description><![CDATA[In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 09:11:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/zetia.html"><![CDATA[Zetia]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_5/ai_n27363190]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) announced today that they have entered into an agreement with Bayer Schering Pharma AG for the discovery of therapeutic antibodies. Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma. Furthermore, these research activities...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 05 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="tickers">BAYR Y</category>
	</item>
</channel>
</rss>
